BEPZY Trademark

Trademark Overview


On Thursday, August 11, 2022, a trademark application was filed for BEPZY with the United States Patent and Trademark Office. The USPTO has given the BEPZY trademark a serial number of 97545112. The federal status of this trademark filing is ABANDONED - EXPRESS as of Friday, March 10, 2023. This trademark is owned by Glaxo Group Limited. The BEPZY trademark is filed in the Pharmaceutical Products category with the following description:

(Based on Intent to Use) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gas...
bepzy

General Information


Serial Number97545112
Word MarkBEPZY
Filing DateThursday, August 11, 2022
Status601 - ABANDONED - EXPRESS
Status DateFriday, March 10, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Services(Based on Intent to Use) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 17, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events


Event DateEvent Description
Friday, March 10, 2023ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Friday, March 10, 2023ABANDONMENT - EXPRESS MAILED
Thursday, March 9, 2023TEAS EXPRESS ABANDONMENT RECEIVED
Wednesday, August 17, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 15, 2022NEW APPLICATION ENTERED